

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

Mcl-1 (D35A5) Rabbit mAb

RRID:AB_10694494

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 5453, RRID:AB_10694494

Antibody Information

URL: http://antibodyregistry.org/AB_10694494

Proper Citation: Cell Signaling Technology Cat# 5453, RRID:AB_10694494

Target Antigen: Mcl-1 (D35A5) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W. Consolidation on 10/2018: AB_10694494, AB_10828726.

Antibody Name: Mcl-1 (D35A5) Rabbit mAb

Description: This monoclonal targets Mcl-1 (D35A5) Rabbit mAb

Target Organism: h, m, mouse, human, mk

Antibody ID: AB_10694494

Vendor: Cell Signaling Technology

Catalog Number: 5453

Record Creation Time: 20250819T215157+0000

Record Last Update: 20250820T002053+0000

Ratings and Alerts

No rating or validation information has been found for Mcl-1 (D35A5) Rabbit mAb.

No alerts have been found for Mcl-1 (D35A5) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. *Cancer research*, 86(6), 1467.

Ma X, et al. (2026) IAP-based biodegraders can convert necroptosis to apoptosis and eliminate cancer driving protein complexes. *Cell chemical biology*, 33(4), 553.

Saleem SK, et al. (2025) JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL. *The Journal of experimental medicine*, 222(1).

Zhang H, et al. (2025) De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. *Nature communications*, 16(1), 6987.

Biber P, et al. (2025) USP9X is a mechanosensitive deubiquitinase that controls tumor cell invasiveness and drug response through YAP stabilization. *Cell reports*, 44(10), 116372.

Yeap HW, et al. (2025) A bacterial network of T3SS effectors counteracts host pro-inflammatory responses and cell death to promote infection. *The EMBO journal*, 44(9), 2424.

He J, et al. (2025) ZBP1 senses spliceosome stress through Z-RNA:DNA hybrid recognition. *Molecular cell*, 85(9), 1790.

Xue F, et al. (2025) CRISPR/Cas9 Screening Highlights PFKFB3 Gene as a Major Contributor to 5-Fluorouracil Resistance in Esophageal Cancer. *Cancers*, 17(10).

Warner K, et al. (2025) Structural ubiquitin contributes to K48 linkage specificity of the HECT ligase Tom1. *Cell reports*, 44(5), 115688.

Harper NW, et al. (2025) RNA Pol II inhibition activates cell death independently from the loss of transcription. *Cell*.

Mustafa EH, et al. (2024) Selective inhibition of CDK9 in triple negative breast cancer. *Oncogene*, 43(3), 202.

Jochems F, et al. (2024) Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state. *Cell death and differentiation*.

Sottnik JL, et al. (2024) WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. *Cancer research communications*,

4(1), 134.

Cazzoli R, et al. (2023) Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition. *Cell reports*, 42(6), 112616.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Mertens S, et al. (2023) Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer. *Cell reports*, 42(4), 112324.

Pei J, et al. (2023) Piperlongumine conjugates induce targeted protein degradation. *Cell chemical biology*, 30(2), 203.

Neault M, et al. (2023) CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax. *Cell reports*, 42(9), 113084.

Perurena N, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. *Cell reports. Medicine*, 4(4), 101007.

McNamara MC, et al. (2022) Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. *iScience*, 25(11), 105458.